These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 11392444)

  • 1. Selective serotonin reuptake inhibitors for late-life depression: a comparative review.
    Solai LK; Mulsant BH; Pollock BG
    Drugs Aging; 2001; 18(5):355-68. PubMed ID: 11392444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
    Sanchez C; Reines EH; Montgomery SA
    Int Clin Psychopharmacol; 2014 Jul; 29(4):185-96. PubMed ID: 24424469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and guide to selection of selective serotonin reuptake inhibitors.
    Edwards JG; Anderson I
    Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.
    Cheer SM; Goa KL
    Drugs; 2001; 61(1):81-110. PubMed ID: 11217873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation-Liaison Service.
    Glass OM; Hermida AP; Hershenberg R; Schwartz AC
    Curr Psychiatry Rep; 2020 Apr; 22(5):21. PubMed ID: 32285305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
    Sánchez C; Hyttel J
    Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on paroxetine.
    Green B
    Curr Med Res Opin; 2003; 19(1):13-21. PubMed ID: 12661775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
    Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
    Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine versus other types of pharmacotherapy for depression.
    Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
    Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine versus other types of pharmacotherapy for depression.
    Cipriani A; Brambilla P; Furukawa T; Geddes J; Gregis M; Hotopf M; Malvini L; Barbui C
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004185. PubMed ID: 16235353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
    van Harten J
    Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
    Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
    JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and safety of fluvoxamine and other antidepressants.
    Westenberg HG; Sandner C
    Int J Clin Pract; 2006 Apr; 60(4):482-91. PubMed ID: 16620364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine: a review.
    Bourin M; Chue P; Guillon Y
    CNS Drug Rev; 2001; 7(1):25-47. PubMed ID: 11420571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.